$HRTX News

HC Wainwright & Co. Downgrades Heron Therapeutics to Neutral

Heron Therapeutics, Inc. (HRTX) Q2 2026 Earnings Call Transcript

Heron Therapeutics Q2 EPS $(0.03) Misses $(0.01) Estimate, Sales $37.666M Miss $42.200M Estimate

Heron Therapeutics In A Tough Spot After Cinvanti Court Loss (Rating Downgrade)

HC Wainwright & Co. Maintains Buy on Heron Therapeutics, Lowers Price Target to $2

Needham Downgrades Heron Therapeutics to Hold

Why Did FULC, MVIS, HRTX Stocks Plunge To 52-Week Lows Today?

U.S. District Court Issues Decision Regarding CINVANTI® Patents

Heron Therapeutics To Appeal Delaware Court Ruling Invalidating Two CINVANTI Patents In Litigation With Azurity

Why Heron Therapeutics, Inc. (HRTX) Price Target Was Reduced to $4 at H.C. Wainwright?

Heron Therapeutics, Inc. 2026 Q1 - Results - Earnings Call Presentation

Heron Therapeutics Inc (HRTX) Q1 2026 Earnings Call Highlights: Resilient Growth Amidst Challenges

Heron Therapeutics Q1 Earnings Call Highlights

Acute Care Revenue Growth Helps Heron (HRTX) Reaffirm 2026 Guidance Despite Q1 Sales Decline

Heron Therapeutics (HRTX) Reports Q1 Earnings: What Key Metrics Have to Say

Heron Therapeutics, Inc. (HRTX) Q1 2026 Earnings Call Transcript

Heron Therapeutics Q1 Results Miss, but Acute Care Growth and Reaffirmed Outlook Support HRTX

Heron Therapeutics (HRTX) Reports Q1 Loss, Lags Revenue Estimates

Heron Therapeutics Announces First Quarter 2026 Financial Results and Reaffirms Guidance

Heron Therapeutics to Report First Quarter 2026 Financial Results on Monday, May 11, 2026